RTTNews | Dec 30, 2020 07:23AM EST

07:23 Wednesday, December 30, 2020 (RTTNews.com) - Bausch Health Companies Inc. (BHC, BHC.TO) said Wednesday that Poland's Office for Registration of Medicinal Products, Medical Devices and Biocidal Products has granted an additional new indication for Dexaven or dexamethasone phosphate solution for injection, 4 mg/ml, for the treatment of SARS-CoV-2 or COVID-19 in adult and adolescent patients-- 12 years of age and older weighing at least 40 kg -- who require oxygen therapy.

Dexaven is a corticosteroid that reduces inflammation.

The U.S. Food and Drug Administration does not approve Dexamethasone-containing products in the United States as a treatment for COVID-19.

Read the original article on RTTNews ( https://www.rttnews.com/3156779/bausch-health-s-dexaven-gets-new-indication-in-poland-to-treat-patients-with-covid-19.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved